Literature DB >> 2341390

Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II).

A Basu1, B A Teicher, J S Lazo.   

Abstract

We have investigated the effect of tumor promoting phorbol esters on the antiproliferative actions of several antitumor agents. Pretreatment of HeLa cells with 12-O-tetradecanoylphorbol 13-acetate (TPA) or phorbol 12,13-dibutyrate (PDBu) caused a significant (9-fold) increase in cellular sensitivity to cis-diamminedichloroplatinum(II) (CP). TPA also sensitized HeLa cells to melphalan (2.5-fold) but had no effect on the antiproliferative activity of bleomycin, doxorubicin, vincristine, or mitomycin C. The sensitization of HeLa cells by TPA was concentration-dependent up to 1 nM and paralleled the activation of protein kinase C by TPA measured in vitro. The maximum stimulation of protein kinase C (6-fold) was observed with 10 nM TPA. 4 alpha-Phorbol 12,13-didecanoate neither activated protein kinase C nor sensitized HeLa cells to CP. 4-O-Methyl-TPA, which does not affect cell cycle distribution of HeLa cells, also sensitized these cells to CP by 6-fold and activated protein kinase C by 3-fold. Inhibitors of protein kinase C, such as palmitoylcarnitine and sphingosine, antagonized PDBu-induced sensitization of HeLa cells to CP. The maximum sensitization of HeLa cells to CP required prolonged pretreatment (greater than or equal to 24 h) with phorbol esters but could not be explained by down-regulation of protein kinase C. For example, 4-O-methyl-TPA caused no down-regulation of protein kinase C. Moreover, TPA caused substantial down-regulation of protein kinase C (1% of control) in A-253 cells but failed to sensitize A-253 cells to CP. TPA (100 nM), however, activated protein kinase C in A-253 cells by 5.5-fold. Therefore, activation of protein kinase C by TPA appears to be necessary but not sufficient for cellular sensitization to CP. The sensitization of HeLa cells by TPA was associated with a concentration- and time-dependent increase in cellular platinum content. The protein synthesis inhibitor cycloheximide (10 micrograms/ml) blocked sensitization of HeLa cells to CP as well as the increase in platinum content caused by a 24-h pretreatment with PDBu.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341390

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Genomic imbalances associated with acquired resistance to platinum analogues.

Authors:  B Leyland-Jones; L R Kelland; K R Harrap; L R Hiorns
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II).

Authors:  K Nishio; Y Sugimoto; Y Fujiwara; T Ohmori; T Morikage; Y Takeda; M Ohata; N Saijo
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

3.  Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

Authors:  Robert J Morgan; Lucille Leong; Warren Chow; David Gandara; Paul Frankel; Agustin Garcia; Heinz-Josef Lenz; James H Doroshow
Journal:  Invest New Drugs       Date:  2010-10-09       Impact factor: 3.850

4.  NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.

Authors:  Eswar Shankar; Chandreyi Basu; Brett Adkins; Wolfram Siede; Alakananda Basu
Journal:  J Mol Signal       Date:  2010-05-10

5.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

6.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin.

Authors:  Elene Pereira-Maia; Arlette Garnier-Suillerot
Journal:  J Biol Inorg Chem       Date:  2003-05-17       Impact factor: 3.358

Review 7.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

8.  Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloroplatinum(II).

Authors:  S S Daoud
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.

Authors:  S Akinaga; K Nomura; K Gomi; M Okabe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.